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Abstract
Background: Physical activity promotion in people with Chronic Obstructive Pulmonary Disease (COPD) is focus of
research and public health. Patient-centred interventions like counselling are promising approaches to help patients
reducing sedentary behaviour. Aim of the present study is to investigate if a physical activity counselling program
during pulmonary rehabilitation increases physical activity level in daily life in people with COPD.
Methods: A two-armed, single blind randomised controlled trial including 56 people with COPD will be conducted in
an outpatient pulmonary rehabilitation. Patients will participate in a 12-week-rehabilitation program; individuals
randomized to the interventional group will additionally participate in five counselling sessions with a physiotherapist,
based on the principles of motivational interviewing. The participants’ physical activity level will be measured using an
accelerometer (SenseWear Pro®) before, directly and 3 months after pulmonary rehabilitation. Semi-structured interviews
will be conducted to learn more about barriers and facilitators regarding daily physical activity.
Discussion: If the strategy successfully improves the physical activity level in people with COPD, counselling might be
implemented in pulmonary rehabilitation.
Trial registration: Clinical Trials.gov NCT02455206 (05/21/2015), Swiss National Trails Portal SNCTP000001426 (05/21/2015).
Keywords: Behaviour change, Physical activity promotion, COPD, Motivational interviewing
Background
Physical inactivity in daily life is a prominent feature in
people with Chronic Obstructive Pulmonary Disease
(COPD) [1–5]. The amount of daily physical activity (PA)
gradually declines with the severity of COPD [5–7]. In
addition, PA is associated with the number of hospitaliza-
tions [8–10] and recognised as the strongest predictor of
all-cause mortality [9, 11] in these patients. A downward
circle of dyspnoea induced by PA may lead to a shift in pa-
tients’ lifestyle resulting in a vicious circle of decreased ex-
ercise tolerance, which in turn further reduces activity
levels and increases social isolation and depression [12]. In
addition, results from the PERCEIVE study indicated that
patients’ perception of their COPD impacted the activities
of daily living [13].
Physical inactivity became topic of great interest since
both the American Thoracic Society (ATS) and the
European Respiratory Society (ERS) stressed the fact that
long-term self-management and adherence to exercise at
home should be the primary goals of pulmonary
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rehabilitation programs (PR) [14]. Research has demon-
strated sufficiently that PR is beneficial to people with
COPD as it improves exercise capacity and locomotor
muscle strength [15, 16]. Although the main purpose of PR
should be enhancing PA, the impact of PR on PA in people
with COPD is still unclear [17, 18]. Mantoani and col-
leagues [19] showed in a literature review that the interven-
tion of 13 studies demonstrated a positive effect while the
strategy of seven studies had no effect. Mantoani and col-
leagues stressed the fact that objectively assessed improve-
ments were only shown by studies with an intervention
phase equal or longer than 12 weeks duration, even though
the increments in activity level ranged between 10 and 20%.
Apparently there is an eloquent difference between
functional capacity status and daily PA, as the latter may
be elicited by the habitual and environmental factors of
sedentary patients. However, in order to be meaningful for
people with COPD, PR-induced improvements need to be
translated into changes in PA and participation in every-
day situations. An alternative strategy to improve physical
activity levels may be a lifestyle PA counselling program to
help the patients to translate PR-induced improvements
in exercise capacity during daily living. It may be postu-
lated that implementation of comprehensive counselling
program during PR is the strategy of choice [20]. One
promising approach is counselling based on motivational
interviewing (MI). According to Miller and Rollnik [21]
this conversation method is client-centred and directive. It
focusses on the exploration and evocation of a person’s in-
trinsic motivation to change his/her status quo regarding
daily physical activity. Hereby MI emphasises the attitude
of rather seeing a person ambivalent than unmotivated in
regards to behavioural change. Consequently, it is the
therapist’s intension to detect a patient’s ambivalence and
to further resolve it. This attitude is called “MI spirit” and
is based on four principles such as; be empathetic, develop
discrepancy, roll with resistance and support self-efficacy
[22]. The process to change the problem behaviour can be
divided in two phases; first to create motivation to change
and second to commit to change. The MI method is self-
defined and not tailored. Several authors investigated the
effects of PA counselling based on MI added to PR in
people with COPD [23–25]. De Blok and colleagues [23]
compared the short-term effects of a lifestyle PA counsel-
ling program with feedback of a pedometer during a nine-
weeks PR on daily step count to PR alone. Twenty-one
individuals with moderate to severe COPD were random-
ized into two groups. Four counselling sessions a 30 min
were performed by physiotherapists following the princi-
ples of MI. The experimental group increased the mean
daily step count by 69% for continuous 6 days without PR,
whereas the control group increased by 19% compared to
baseline. Effects were not statistically significant, however
the between-group effect size was d > 0.8. This was the
first study using a feedback-tool to improve motivation
which gave useful information for following trials evaluat-
ing long-term effects in a larger patient group living in the
region of Groningen [26, 27]. However, PA was quantified
by using a pedometer, but objectively measuring PA by
using multiaxial accelerometer seems to be the most ac-
curate field based estimate of PA [28, 29]. Burtin and col-
leagues [24, 25] investigated as well the additional effect of
counselling during PR in PA levels in 80 people with mod-
erate to very severe COPD. To measure PA levels object-
ively an accelerometer was used before and after 3 months
and after 6 months of PR. Those individuals randomized
to the intervention group participated in eight individual
counselling sessions a 20 to 30 min with a physiotherapist
based on principles of MI. Controls received a sham atten-
tion program. Unfortunately, the study failed to show any
improvements regarding PA after 6 months. The authors
reflect it could be more effective to put the counselling
sessions at the end respectively short after the end of PR.
Furthermore, the counselling providers had no prior ex-
perience with MI. They have had three 1 h–training ses-
sions and supervision during the first few months of the
study. Additionally, adherence to PR was not documented.
Holland and colleagues [30] published a protocol de-
scribing a RCT in 166 individuals evaluating the effect of
home-base PR using MI compared to outpatient PR. It is
an eight-week program and primary outcome will be the
immediate change in six-minute walk distance.
Designing the optimal intervention for the promotion
of PA in people with COPD is an intensively investi-
gated topic in recent literature [19, 20, 31]. In order to
address the recommendations of the ATS and the ERS
more accurately, the current study aims to improve
long-term self-management and adherence to exercise
at home during PR by adding counselling based on MI.
This study also aims to gain information about the will-
ingness to actually change habitual behaviour in
patients with COPD and evaluates the patients’ per-
spective on barriers and facilitators towards daily PA.
There is no conclusive evidence yet about the best
strategy to promote PA and helping people with COPD
to change their behaviour. Data from well-designed
interventional studies looking at the willingness to ac-
tually change habitual behaviour in people with COPD
are urgently needed [20]. The results of the study may
gain insight into the factors determining physical activ-
ity and help leading to novel therapeutic approaches in
the care of people with COPD.
Objective
The overall aim of the present study is to investigate
if a PA counselling program during outpatient PR in-
creases PA level in daily life in people with COPD
during and after PR.
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Methods
Design and ethics
The study is a prospective two-arm single-blinded
randomized controlled trial comparing a PA counsel-
ling group (PAcG) with a usual care control group
(CG). Figure 1 shows a flow chart of the study. The
study was approved by the local ethics committee
(Canton Zurich) on 4th May 2015 (PB_2016–01523)
and inclusion was initiated in October 2015 (still
ongoing).
The data collection will be conducted in compliance
with Good Clinical Practices protocol and the Declar-
ation of Helsinki principles. The participants with
COPD will receive written and oral information about
the study. Written informed consent will be obtained
prior to baseline measurements. The study is regis-
tered on the website of http://www.ClincalTrails.gov
with the identifier NCT02455206 as well as the Swiss
National Trails Portal SNCTP000001426.
Setting
This study will be conducted at Canton Hospital
Winterthur (KSW; Institute for Physiotherapy and Pul-
monary Division), Switzerland. Patients participate in
the outpatient PR program “Pneumofit”.
Participants
Participants fulfilling all of the following inclusion criteria
are eligible for the study: Informed consent as documented
by signature aged 40–90 years and confirmed COPD
(GOLD stages B-D) according to GOLD-guidelines [12],
German speaking and planned participation in Pneumofit.
The presence of any one of the following exclusion criteria
will lead to exclusion of the participant: Mental or physical
disability (known mini-mental score < 20) precluding
informed consent or compliance with the protocol, pa-
tients on morphine medication, primary diagnosis of heart
failure, uncontrolled arrhythmias causing symptoms or
hemodynamic compromise, severe co-morbidity (acute
coronary syndrome, unstable angina terminal renal failure,
concomitant pulmonary embolism, very severe pneumonia:
CURB65 > 3), severe untreated arterial hypertension at rest
(> 200 mmHg systolic, > 120 mmHg diastolic). Criteria for
withdrawal are defined as cordial ischemia, fall in systolic
pressure > 20 mmHg from the highest value during the
test, hypertension (> 250 mmHg systolic; > 120 mmHg
diastolic), recurrent exacerbation, interruption of
rehabilitation program ≥3 weeks. Withdrawn participants
will be contacted 3 month after the last visit. They will be
asked if they would like to participate in the follow-up as-
sessment (accelerometer, questionnaires) and focus-group
Fig. 1 Design and flow of participants through the trial
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interviews. We will record any adverse events such as in-
juries, increase of respiratory symptoms or cardiac events
as they happen during the outpatient PR.
Recruitment and randomization
People with confirmed COPD according to the guidelines
referred to the pulmonary division of KSW between
October 2015 and likely October 2018 will be asked to par-
ticipate in the study. No public advertisement will be per-
formed. Using a generator (R statistical software) the
patients will randomly allocated into blocks of four, within
one of two treatment arms. Additionally, stratification is
used to ensure good balance of exercise capacity (6MWD).
The randomization list will be accessible to the responsible
members of the research team. The individual assignment
will be kept in closed envelopes, which will be opened after
the patient gives his/ her consent to participate in the study.
Randomization will be performed by an independent per-
son. For practical reasons participants and therapists are
not blinded, but the assessors will be blinded.
Intervention
Pneumofit
Cardio-pulmonary exercise training will be performed ac-
cording to published guidelines [19, 32–34]. Participants
attend the outpatient clinic three times per week (1.5-h
sessions) for 12 weeks performing 36 sessions of physical
training. The sessions include dynamic strength training
for the following muscles: quadriceps femoris, hamstrings,
triceps surae, pectoralis major, deltoid, latissimus dorsi
and triceps brachi. The dynamic strength training exer-
cises will be performed while seated. Patients start at 70%
of their initial one-repetition maximum (1RM) and fulfill
2 cycles of 6-12repetitions of isotonic muscle contractions
[32–34] with a resting period of 1–2 min between the
series. One repetition maximum (1RM) is the maximum
amount of weight one can lift during a single repetition of
a given exercise.
When the patients feels able to perform three sets of
more than 15 repetitions without any difficulty, effort will
be increased stepwise by 5% of the 1RM. Cardio-
pulmonary endurance training will be performed on a
cycle ergometer or treadmill [32–34]. The initial intensity
for cycling will be set at 70–80%Wpeak for 20 min. In-
creases in workload will be based upon symptom scores.
Interval endurance training will be performed according
to the recommendations by Gloeckl and colleagues [35].
Participants perform one training per week outdoors par-
ticipating in a nordic walking class.
Experimental group
Participants allocated to PAcG will receive PR plus
counselling. PA counselling will be performed by using
“motivational interviewing” (MI) techniques. The PA
counselling will be provided by two experienced physio-
therapists (MSc.), independent to the rehabilitation pro-
gram, who are profoundly trained and graduated by a
9 days MI course. There are going to be five face-to-face
conversations a 30 min between the therapist and one
patient during the twelve-week rehabilitation program
“Pneumofit” at KSW. Privacy during the sessions will be
ensured. The dates of the session will be organised by
the receptionists of the physiotherapy institute of KSW
and the ZHAW. In case of missing out, the session will
be held within the shortest possible timeframe.
Evaluation of communication skills of counsellors/
fidelity check If the participant of the PAcG agrees all
counselling sessions will be audiotaped. The fidelity
check evaluates the general session content, as well as
random 20-min segments of the conversations which
will be assessed by an external independent MI-expert
according to the Motivational Interviewing Treatment
Integrity (MITI 4) [36] criteria. Feedback will be pro-
vided to the counsellors to strengthen their skills and
consistency with the study intervention [37].
Controls
Participants allocated to the control group will receive
usual care PR.
Measurements
Before beginning of PR program, baseline pulmonary
function test and other routine assessments will be per-
formed. In addition, study specific assessments will be
conducted. The patients are asked to wear an accelerom-
eter during seven consecutive days. Furthermore, the pa-
tients are invited to fill out four different questionnaires
(BREQ-3, SCPA, IPAQ, and CRQ). Assessments will be
conducted at baseline (week 0), after 3 month when fin-
ishing PR (week 12), and patients will be contacted for
the follow-up assessment (week 24). Additionally, partic-
ipants will be asked to take part in interviews for a quali-
tative analysis.
Daily physical activity (PA)
PA will be measured by a multisensor accelerometer (Sen-
seWear Pro® armband; BodyMedia, Inc., Pittsburgh, PA,
USA), which is worn on the upper right arm. The device
estimates energy expenditure (EE) using measurements
from a biaxial accelerometer and sensors that quantify gal-
vanic skin response, heat flux and skin temperature. The
biaxial accelerometer records the number of steps per day
and the duration of PA [38]. The number of steps per day,
metabolic equivalent (MET), total energy expenditure
(TEE), and the physical activity level (PAL) will be used in
the present study. Primary outcome is number of steps
per day. MET, TEE, PAL are secondary outcomes. PAL is
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calculated using TEE and sleep expenditure as a surrogate
for resting energy expenditure (REE) (PAL = TEE/REE).
The patients will be instructed to wear the accelerometer
continuously during seven consecutive days, except when
bathing or showering. The SenseWear Pro® armband was
validated to accurately measure PA and quantify EE in pa-
tients with COPD [28, 29, 39].
Behaviour exercise regulation questionnaire (BREQ-3)
The BREQ-3 [40] considers the individuals’ motivation
towards exercise. The questionnaire comprises 24 items
relating to five motivation types from the Self-
determination Theory [41]. Each item is measured on a
scale, from 0 (“Not true to me”) to 4 (“very true to me”).
The BREQ-2 was already used in the context of PA re-
search [42, 43]. BREQ-3 was translated into German fol-
lowing guidelines for translation and cross-cultural
adaption of self-report measures [44–46].
Physical activity stage of change assessment tool (PASC)
The Physical Activity Stage of Change Assessment Tool
[47] was designed to assess the patients’ willingness to
change their habitual behaviour using a brief series of
four questions based on the transtheoretical model [38].
PASC was translated into German following guidelines
for translation and cross-cultural adaption of self-report
measures [44, 45, 48].
Awareness of physical activity
The awareness of the PA level will be evaluated by the
German International Physical Activity Questionnaire
(IPAQ) [49, 50]. The IPAQ considers a 7-day recall period,
identifying PA undertaken in the morning, afternoon and
evening. IPAQ quantifies PA by using the time send on
walking, moderate and vigorous PA. The IPAQ was used
in patients with COPD in previous research [51].
Compliance to PR
Compliance is defined as the number of sessions com-
pleted divided by the total number of sessions prescribed
and will be expressed as a percentage. The Program
Pneumofit at KSW consists of minimal 24 and maximal
36 training sessions.
Health-related quality of life (CRQ)
The Chronic Respiratory Disease Questionnaire (CRQ) is a
disease-specific assessment for evaluating COPD [52]. The
CRQ-Questionnaire has been validated to quantify the im-
pact of disease on daily life and well-being [53]. The CRQ
consists of 20 items, which can be divided into four do-
mains: dyspnoea (five items), fatigue (four items), emotional
function (seven items) and mastery (four items). The pa-
tients will be asked to rate each item on a 7-point scale
from 1 (maximum impairment) to 7 (no impairment).
Higher scores imply better self-reported disease-specific
QOL. The total CRQ score, calculated as the mean of the
scores on the four dimensions of the CRQ, will be used for
further analysis.
COPD assessment test (CAT)
The CAT score is a unidimensional patient-completed
questionnaire assessing globally the impact of COPD
(cough, sputum, dysnea, chest tighteness) on health sta-
tus [54]. The CAT scores range from 0 to 40. Higher
scores denote a more severe impact of COPD on a pa-
tient’s life. The difference between stable and exacerba-
tion patients was five units. No target score represents
the best achievable outcome.
Cardiopulmonary exercise capacity
The incremental work-rate test permits the evaluation of
both submaximal and peak exercise responses, providing
several indices relevant to the evaluation of patients with
respiratory diseases. Use of the IET can also rule out cer-
tain medical conditions that pose a risk for exercise inter-
ventions, thus increasing their safety. Also, exercise tests
are reliable and consistently responsive to rehabilitative
and pharmacological interventions. Symptom-limited car-
diopulmonary exercise testing will be performed using an
electronically braked cycle ergometer (Ergoselect 200).
After an initial 3 min of unloaded pedalling, the work load
will be increased automatically by 5–8 watts every minute
until the patient could no longer continue the required ca-
dence of 55–65 rpm due to dyspnea or exhaustion.
Maximum work rate (Wmax) will be defined as the
highest work level that was reached. Oxygen saturation
(measured via pulse oximetry) and heart rate (measured
via electrocardiography) will be recorded continuously
throughout exercise and during recovery.
Six-minute walk test (6MWT)
The Six-minute walk test (6MWT) will be performed ac-
cording to the guidelines published by the ATS [55] with a
standardized encouragement in a 30 m corridor. An expe-
rienced technician will supervise it. Before starting the
6MWT, patients will be seated for three to 5 min. The
Spirometry will be performed prior to the test. The
6MWT will be followed by a recovery phase, where the
patient will rest on a chair. Total walking distance, Borg’s
dyspnoea score and the subjective limiting factor (accord-
ing to the patients’ interpretation) will be measured.
Sit to stand (STS)
Furthermore, the sit-to-stand-test (STS) will be per-
formed according to Puhan and colleagues [56]. Using
the STS test protocol, an experienced physiotherapist
will ask patients to sit down on a chair (height 46–
48 cm) without arm rests, keep their legs apart with
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about 90 degrees knee flexion and aligned with their
hips, and to hold their hands stationary on their hips.
Patients will be asked to stand up and to sit down once
or twice in order to familiarize them with the task and
to assess its feasibility and safety. A physiotherapist in-
structs patients about the duration of the test (1 min)
and to perform as many repetitions as possible allowing
for short breaks if needed but without using the arms
for support. The physiotherapist starts the test by giving
the command “attention, ready, go”. When 15 s are left
patients will be told “You have 15 seconds left until the
test is over”.
Pulmonary function
Participants will receive spirometry, whole body plethys-
mography and diffusion capacity measurements according
to the ATS/ERS guidelines with a commercially available
system (Body 500™, ZAN, Oberthulba, Germany) [57].
Post bronchodilator spirometry will be performed after in-
halation of 4 × 100 μg salbutamol. Maximal inspiratory
mouth occlusion pressure after 100 ms (PO.1max) will be
measured as previously described [57].
Barriers and enablers PA
Individual, semi-structured interviews will be performed
in a subgroup of 16 participants in order to gain more de-
tailed information about “barriers and enablers” of partici-
pation in daily-life activities. Participants will be invited to
two interviews, one right after PR the other after 3 months
follow up. Discussions will be audiotaped, transcribed at
verbatim, coded and categorized according to upcoming
themes. A content analysis will be performed.
Research questions are:
 What are motivating and limitating factors to be
physically active for patients with COPD?
 Does PR change the patients’ attitude towards PA?
How?
 What can we learn for “Pneumofit”?
Statistics
Statistical model
Applying random intercept models, we model the continu-
ous response ygtk (number of steps) of subject k(k = 1, . . .,
n) at time t (baseline t = 0, follow-up t = 1) in treatment
arm g (control: g = 0, intervention g = 1). The model is
ygtk = μ + γg + τt + (γτ)gt + Sk + (Sτ)k , t .
Fixed effects: μ is the mean outcome in the control at
baseline, γ1 is the difference at baseline between the mean
of the intervention and control group (γ0 = 0) - in random-
ized controlled trials, we expect that γ1 = 0, τ1 is the change
from baseline to follow-up of the control means (τ0 = 0),
δ = (γτ)11 is the difference in change from baseline between
intervention and control means (for g ≠ 1 or t ≠ 1:
(γτ)gt = 0). This is the quantity of interest!
Random effects: the random effects Sk, (sτ)k,t are nor-
mally distributed with mean 0 and variance σ2s , σ
2
sτ , re-
spectively. Thus, the (unconditional) variance of the
response γgtk is σ2 ¼ σ2s þ σ2sτ . The sk, (sτk , t)k,t describe
the variation of subjects in time-invariant and time-
varying part. Subject autocorrelation The subject auto-
correlation defined by ρs ¼ σ
2
s
σ2sþσ2sτ describes the correl-
ation of the subject specific scores sk + (sτ)k , t.
Sample size calculation
We make the assumption based on prior literature findings
[27] that our counselling will yield a larger difference be-
tween the two groups: after 3 months of therapy, the pa-
tients in the experimental group walk 3000 steps per day
(SD = 4000) more than the patients in the control group.
The randomized trial will be analysed using ANCOVA
with the outcome at baseline as a covariate. The ap-
proach to power calculations can be resumed: a trial of
(1 –ρ2)n subjects analysed via ANCOVA has the same
power as a trial of n subjects analysed on the follow-up
scores, ρ representing the subject autocorrelation be-
tween baseline and follow-up. The design effect is thus
given by (1 − ρ2). For an equality study, we have the hy-
pothesis H0: δ = 0, H1: δ ≠ 0. With an effect size of
3000/4000 = 0.75, the per-group sample size is, using a
power of 0.8, α = 0.05 and a conservative estimation of
the within-subject autocorrelation of ρ = 0.5, n = 22.
Considering a drop-out rate of 25%, a total of 56 pa-
tients (28 in each group) need to be recruited.
Statistical analysis
The data will be analysed with ANCOVA using baseline
values as covariates. As described above, this analysis is the
most efficient. In the analysis stage, no null-hypothesis sig-
nificance testing-procedures (NHSP) will be used. Instead,
we will use a modern Bayesian approach with Markov
Chain Monte Carlo methods (MCMC) and non-
informative priors on the unknown quantities. Bayesian in-
ference is the reallocation of credibility across the space of
candidate possibilities for the unknown quantities and
gives much richer information than classical frequentist
procedures. The Bayesian approach results in the posterior
distributions of all unknown quantities (parameters and
missing values), therefore allowing unambiguous probabil-
ity statements about the quantities of interest those are not
possible in a frequentist framework. In addition, the com-
putation of derived quantities (such as contrasts of interest)
is straight forward. Ninety-five percent Bayesian credible
intervals will be constructed for the parameters of interest.
All analyses will be performed using the R statistical soft-
ware R version 3.3.2 (2016–10-31) [58] and JAGS (Just
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Another Gibbs Sampler) [59]. JAGS is designed to work
with the R language. From within R, we will use the rjags-
package [60].
Discussion
The development and implementation of successful strat-
egies to improve PA are in the focus of both, medical re-
search and public health [8–11]. The minimal important
difference regarding a proxy of PA has not been defined yet
in people with COPD. PA recommendations for the elderly
state that 30 min of moderate intense physical activity on at
least 5 days per week in order to improve or maintain their
health status [61]. But even these recommendations are not
realistic for people with very severe COPD. There seems to
be a common agreement that PA promotion in people with
COPD has to incorporate the patients’ personal values and
goals, symptoms, and motivation status [20, 24, 25, 62, 63].
Donaire-Gonzales and colleagues [64] evaluated the inter-
action of quantity and intensity of PA in their effects on
COPD hospitalisation risk. For people with low average PA
intensity the risk for COPD hospitalisation was reduced by
20% for every additional 1000 daily steps. Contrary and a
little surprising, adding steps to an anyway high-intensity
PA does not produce any risk reduction. Reducing seden-
tary behaviour is especially beneficial for people with low
PA. Currently, it is still on debate which strategy might be
the best to improve PA in people with COPD. Recent litera-
ture shows a tendency to patient-centred interventions like
counselling [19]. This study aims to investigate if a PA
counselling program based on the principles of MI, during
PR increases PA level in daily life in people with COPD.
Using a mixed-method-approach will gain multifaceted
knowledge about barriers and facilitators about the accept-
ance and effect of this strategy.
It might be a disadvantage not to offer direct feedback
like a pedometer to every participant [19]. However, if a
participant has the idea to use a step counter (pedometer,
mobile phone, etc.) as part of his strategy to be more active,
we support this purpose.
The accelerometer SenseWear is especially accurate and
validated in this patient group [39, 65], but not easy access-
ible in clinical practice. The device is much more uncom-
fortable and unattractive than other devices like a smart
watch. Furthermore, the SenseWear device production was
stopped in 2015. Anyhow, we decided to stick with the
SenseWear.
If this strategy is approved to be effective PA counselling
might be implemented as an integral part of PR Pneumofit.
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